v3.25.2
CONSOLIDATED STATEMENTS OF CHANGES IN MEZZANINE AND SHAREHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
PSUs
Class A Common Stock
Class A Common Stock
PSUs
Additional Paid-In Capital
Additional Paid-In Capital
PSUs
Accumulated Other Comprehensive Income (Loss)
Retained Earnings (Accumulated Deficit)
Treasury Stock
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2023 175,000                
Series A preferred stock , beginning balance at Dec. 31, 2023 $ 178,427                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Net loss attributable to common shareholders of Evolent Health, Inc. $ 5,779                
Series A preferred stock , ending balance (in shares) at Jun. 30, 2024 175,000                
Series A preferred stock , ending balance at Jun. 30, 2024 $ 184,206                
Beginning balance (in shares) at Dec. 31, 2023     115,425,000            
Beginning balance at Dec. 31, 2023 1,067,701   $ 1,154   $ 1,808,121   $ (1,257) $ (719,194) $ (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation expense 31,445       31,445        
Exercise of stock options (in shares)     101,000            
Exercise of stock options 1,119   $ 1   1,118        
Restricted stock units vested, net of shares withheld for taxes (in shares)     531,000            
Restricted stock units vested, net of shares withheld for taxes (10,134)   $ 6   (10,140)        
Performance stock units vested, net of shares withheld for taxes (in shares)       205,000          
Performance stock units vested, net of shares withheld for taxes   $ (4,564)   $ 2   $ (4,566)      
Foreign currency translation adjustment (98)           (98)    
Net (loss) income attributable to common shareholders of Evolent Health, Inc. (31,608)       (15,924)     (15,684)  
Ending balance (in shares) at Jun. 30, 2024     116,262,000            
Ending balance at Jun. 30, 2024 $ 1,053,861   $ 1,163   1,810,054   (1,355) (734,878) (21,123)
Series A preferred stock , beginning balance (in shares) at Mar. 31, 2024 175,000                
Series A preferred stock , beginning balance at Mar. 31, 2024 $ 181,294                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Net loss attributable to common shareholders of Evolent Health, Inc. $ 2,912                
Series A preferred stock , ending balance (in shares) at Jun. 30, 2024 175,000                
Series A preferred stock , ending balance at Jun. 30, 2024 $ 184,206                
Beginning balance (in shares) at Mar. 31, 2024     116,195,000            
Beginning balance at Mar. 31, 2024 1,047,936   $ 1,162   1,805,679   (1,308) (736,474) (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation expense 12,659       12,659        
Exercise of stock options (in shares)     5,000            
Exercise of stock options 60       60        
Restricted stock units vested, net of shares withheld for taxes (in shares)     62,000            
Restricted stock units vested, net of shares withheld for taxes (364)   $ 1   (365)        
Foreign currency translation adjustment (47)           (47)    
Net (loss) income attributable to common shareholders of Evolent Health, Inc. (6,383)       (7,979)     1,596  
Ending balance (in shares) at Jun. 30, 2024     116,262,000            
Ending balance at Jun. 30, 2024 $ 1,053,861   $ 1,163   1,810,054   (1,355) (734,878) (21,123)
Series A preferred stock , beginning balance (in shares) at Dec. 31, 2024 175,000                
Series A preferred stock , beginning balance at Dec. 31, 2024 $ 190,173                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Net loss attributable to common shareholders of Evolent Health, Inc. $ 38,627                
Series A preferred stock , ending balance (in shares) at Jun. 30, 2025 175,000                
Series A preferred stock , ending balance at Jun. 30, 2025 $ 228,800                
Beginning balance (in shares) at Dec. 31, 2024 116,575,773   116,576,000            
Beginning balance at Dec. 31, 2024 $ 1,001,259   $ 1,166   1,803,786   (1,753) (780,817) (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation expense 22,661       22,661        
Restricted stock units vested, net of shares withheld for taxes (in shares)     585,000            
Restricted stock units vested, net of shares withheld for taxes (2,799)   $ 6   (2,805)        
Performance stock units vested, net of shares withheld for taxes (in shares)       312,000          
Performance stock units vested, net of shares withheld for taxes   $ (1,822)   $ 3   $ (1,825)      
Foreign currency translation adjustment 46           46    
Net (loss) income attributable to common shareholders of Evolent Health, Inc. $ (123,340)       (38,825)     (84,515)  
Ending balance (in shares) at Jun. 30, 2025 117,472,681   117,473,000            
Ending balance at Jun. 30, 2025 $ 896,005   $ 1,175   1,782,992   (1,707) (865,332) (21,123)
Series A preferred stock , beginning balance (in shares) at Mar. 31, 2025 175,000                
Series A preferred stock , beginning balance at Mar. 31, 2025 $ 193,228                
Increase (Decrease) in Temporary Equity [Roll Forward]                  
Net loss attributable to common shareholders of Evolent Health, Inc. $ 35,572                
Series A preferred stock , ending balance (in shares) at Jun. 30, 2025 175,000                
Series A preferred stock , ending balance at Jun. 30, 2025 $ 228,800                
Beginning balance (in shares) at Mar. 31, 2025     117,398,000            
Beginning balance at Mar. 31, 2025 935,521   $ 1,174   1,802,634   (1,729) (845,435) (21,123)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock-based compensation expense 11,580       11,580        
Restricted stock units vested, net of shares withheld for taxes (in shares)     75,000            
Restricted stock units vested, net of shares withheld for taxes (28)   $ 1   (29)        
Foreign currency translation adjustment 22           22    
Net (loss) income attributable to common shareholders of Evolent Health, Inc. $ (51,090)       (31,193)     (19,897)  
Ending balance (in shares) at Jun. 30, 2025 117,472,681   117,473,000            
Ending balance at Jun. 30, 2025 $ 896,005   $ 1,175   $ 1,782,992   $ (1,707) $ (865,332) $ (21,123)